Intervention

Saruparib

ClinicalTrials.gov intervention label

Clinical trials5

Recruiting3

Common conditions12

Lead sponsors shown2

Clinical trials

5 shown

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM StudyNCT06769126 · 2025-11-06

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA MutationNCT06952803 · 2025-08-06

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid TumorsNCT05797168 · 2023-06-05

Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)NCT07711002 · 2026-10-01

NOT_YET_RECRUITING

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal AgentsNCT06120491 · 2023-11-21

ACTIVE_NOT_RECRUITING

Common conditions

Endometrial Cancer1 Extensive Stage Lung Small Cell Carcinoma1 Lung Adenocarcinoma1 Lung Small Cell Carcinoma, A Subtype1 Lung Small Cell Carcinoma, I Subtype1 Lung Small Cell Carcinoma, N Subtype1 Lung Small Cell Carcinoma, P Subtype1 Lung Squamous Cell Carcinoma1 Metastatic Castration-Sensitive Prostate Cancer1 Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)1 Ovarian Cancer1 Prostate Cancer1

Leading sponsors

AstraZeneca4 SWOG Cancer Research Network1

Trial status mix

RECRUITING3

ACTIVE_NOT_RECRUITING1

NOT_YET_RECRUITING1

Phase mix

PHASE33

PHASE22

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.